Infections by Herpes Zoster (HZ) in patients on tsDMARDs (randomised controlled trials)
| Study ID (trial) | Follow-up (weeks) | Treatment arm | N patients | HZ n (%) | Risk of bias |
| PBO-controlled trials | |||||
| Genovese et al 86 2019 | 24 | FIL 200 + csDMARD | 147 | 2 (1.4) | Low |
| FIL 100 + csDMARD | 153 | 2 (1.3) | |||
| PBO + csDMARD | 148 | 0 (0.0) | |||
| Kameda et al 89 2020 | 12 | UPA 7.5+ csDMARD | 49 | 1 (2.0) | Low |
| UPA 15+ csDMARD | 49 | 0 (0.0) | |||
| UPA 30+ csDMARD | 50 | 3 (6.0) | |||
| PBO+ csDMARD | 49 | 1 (2.0) | |||
| Active-comparator trials | |||||
| Combe et al 77 2021 | 24 | FIL 200+MTX | 475 | 2 (0.4) | Low |
| FIL 100+MTX | 480 | 2 (0.4) | |||
| ADA+MTX | 325 | 2 (0.6) | |||
| PBO+MTX | 475 | 2 (0.4) | |||
| Fleischmann et al 80 2019 | 26 | UPA+MTX | 650 | 5 (0.8) | Low |
| ADA+MTX | 327 | 1 (0.3) | |||
| PBO+MTX | 652 | 3 (0.5) | |||
| Rubbert-Roth et al 93 2020 | 24 | UPA 15+csDMARD | 303 | 4 (1.3) | Low |
| ABA+csDMARD | 309 | 4 (1.3) | |||
| Smolen et al 94 2019 | 14 | UPA 15 | 217 | 3 (1.0) | Low |
| UPA 30 | 215 | 6 (3.0) | |||
| MTX | 216 | 1 (<1) | |||
| van Vollenhoven et al 101 2020 | 24 | UPA 15 | 317 | 7 (2.2) | Low |
| UPA 30 | 314 | 7 (2.2) | |||
| MTX | 314 | 1 (0.3) | |||
| Westhovens et al 102 2021 | 52 | FIL 200+MTX | 416 | 6 (1.0) | Low |
| FIL 100+MTX | 207 | 3 (1.0) | |||
| FIL 200 | 210 | 4 (2.0) | |||
| MTX | 416 | 4 (1.0) | |||
ABA, abatacept; ADA, adalimumab; csDMARD, conventional synthetic disease-modifying antirheumatic drug; FIL, filgotinib; HZ, herpes zoster; MTX, methotrexate; PBO, placebo; tsDMARD, targeted synthetic DMARD; UPA, upadacitinib.